CGON (CG Oncology) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 26, 2026)


CGON CG Oncology Inc CGON
12 GF Score
Price $71.96
! 6 Warning Signs
View Full Analysis

What is CG Oncology Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

CG Oncology's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

CGON vs CRSP, XENE, TGTX: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, CG Oncology's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CG Oncology Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CG Oncology's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where CG Oncology's Margin of Safety % (DCF FCF Based) falls into.


CGON
12GF Score
CG Oncology Inc CGON
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CG Oncology Business Description

Address 400 Spectrum Center Drive, Suite 2040, Irvine, CA, USA, 92618
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
12GF Score

Get the complete analysis for CGON

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$71.96
Price